It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
This study evaluates dosimetric differences in Stereotactic Body Radiation Therapy (SBRT) for lung tumors using plans of Gamma Knife, and Volumetric Modulated Arc Therapy (VMAT), Intensity-Modulated Radiation Therapy (IMRT) plans based on Linear Accelerator, aiming to inform the reader of appropriate treatment strategy selection. Ten patients with 23 lung tumor lesions treated with SBRT at Zhongshan Hospital of Dalian University were analyzed. Plans of Gamma Knife, and VMAT, IMRT plans based on Linear Accelerator were created for each lesion, totaling 18 plans per type. Lesions were treated with 30–50 Gy in 5–10 fractions. Dosimetric parameters, including gradient index (GI), heterogeneity index (HI), conformity index (CI), and doses to the plan target volumes (PTVs), the gross tumor volumes (GTVs) and organs at risk (OARs) were compared. Plans of Gamma Knife showed superior HI and GI, higher PTV and GTV doses, and reduced doses to the ipsilateral and contralateral lungs, esophagus, spinal cord, and heart compared to VMAT and IMRT plans (p < 0.05). However, Plans of Gamma Knife required longer delivery times. When comparing VMAT and IMRT plans, VMAT plans had shorter delivery times than IMRT plans, but required more monitor units (MUs). Additionally, IMRT plans delivered a lower mean dose to the ipsilateral lung compared to VMAT plans. Gamma Knife SBRT plans achieves steeper dose falloff and minimizes radiation to normal lung tissue compared to VMAT and IMRT plans, but with longer delivery times. VMAT and IMRT plans displayed similar dose distributions for lung SBRT.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Affiliated Zhongshan Hospital of Dalian University, Department of Radiotherapy, Dalian, P. R. China (GRID:grid.459353.d) (ISNI:0000 0004 1800 3285); Dalian University, The Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Dalian, P. R. China (GRID:grid.440706.1) (ISNI:0000 0001 0175 8217); Dalian University, The Key Laboratory of Radioactive Particles and Thermal Precision Therapy, Dalian, P. R. China (GRID:grid.440706.1) (ISNI:0000 0001 0175 8217)
2 Affiliated Zhongshan Hospital of Dalian University, Department of Medical Oncology, Dalian, P. R. China (GRID:grid.459353.d) (ISNI:0000 0004 1800 3285); Dalian University, The Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Dalian, P. R. China (GRID:grid.440706.1) (ISNI:0000 0001 0175 8217); Dalian University, The Key Laboratory of Radioactive Particles and Thermal Precision Therapy, Dalian, P. R. China (GRID:grid.440706.1) (ISNI:0000 0001 0175 8217)
3 Affiliated Zhongshan Hospital of Dalian University, Department of Medical Oncology, Dalian, P. R. China (GRID:grid.459353.d) (ISNI:0000 0004 1800 3285); Graduate School of Dalian Medical University, Dalian, P. R. China (GRID:grid.411971.b) (ISNI:0000 0000 9558 1426)